Diaceutics' suite of companion diagnostic commercialization services puts patients first at ASCO 2019 | Diaceutics

Diaceutics’ suite of companion diagnostic commercialization services puts patients first at ASCO 2019

May 7th, 2019



Patients themselves are the focus of this year’s annual meeting of the American Society of Clinical Oncology (ASCO), which will be held May 31 through June 4, 2019 at McCormick Place in Chicago, Illinois. The meeting’s official theme is “Caring for Every Patient, Learning from Every Patient.” That focus on the patient starts with an early and accurate diagnosis, which is the mission of Diaceutics.

In the words of the CEO of Diaceutics, Peter Keeling, “Diaceutics was founded out of a desire to get more patients access to improved healthcare. We are giving patients a higher likelihood of getting better by supporting access to the right test to determine the right treatment at the right time.”

And that’s why Diaceutics will be onsite at ASCO 2019 inviting all those interested in learning more about options in partnering for companion diagnostic commercialization (click here to learn more about Diaceutics at ASCO 2019). A data analytics and implementation services provider focused strictly on precision medicine, Diaceutics has established a suite of data-driven products powered by the real-world diagnostic testing data held in its proprietary database. These solutions are focused on optimizing our pharmaceutical clients’ strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines—ultimately putting patients first in the diagnostic patient journey.

Diaceutics’ services fall into the following 4 sequential modules:

  • Landscape – Comprehensive reviews of the testing environment for pharmaceutical companies, identifying risks and opportunities while providing essential insight into the strategic decisions that need to be made in advance of a launch.
  • Planning – Advising on steps to ensure rapid and effective test adoption, including advice on how tests should be developed, who these tests should be developed with, and how they may be optimally communicated to physicians and patients.
  • Implementation – Identifying and solving issues with leading laboratories relating to the adoption and efficacy of testing.
  • Tracking – Ongoing post launch analysis to understand how tests are being adopted and utilized to determine if they are promoting or restricting access to precision therapy.

Learn more about Diaceutics by clicking here.

Diaceutics recently became the fourth Northern Irish company to list on the London Stock Exchange with its initial public offering (IPO) on March 21, 2019. Diaceutics is currently trading under the AIM ticker symbol DXRX. The IPO is a testament to Diaceutics’ commitment to patients everywhere, following 13 years spent on the ground mining the diagnostic testing market, collating large amounts of laboratory, patient (anonymized and aggregated), claims and payor data in order to deliver companion diagnostic strategies to clients.

Find out how partnering with Diaceutics may help you help patients live longer and enjoy a better quality of life through earlier, accurate diagnostic testing. Arrange to meet one of our experts on companion diagnostic commercialization by clicking here.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn